Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

View Full Paper
Ask AI
Bookmark
Share

Authors

ZZZeping ZhouHLHeng LiPGPengxiang Guo

Discussion

Loading...

Member takes

Overview

Randomized trial shows DEC3-VEN improves remission rates in elderly patients with acute myeloid leukemia, suggesting enhanced efficacy over azacitidine.

Key Points

  • This trial investigates the safety and efficacy of DEC3-VEN in elderly patients with acute myeloid leukemia (AML).
  • Phase III, prospective, multicenter, randomized controlled trial
  • Enrolled patients aged 60 or older or unfit for intensive chemotherapy
  • Experimental group received DEC3-VEN therapy; control group received VEN plus azacitidine
  • DEC3-VEN group showed a complete remission (CR) rate of 73.1% and a minimal residual disease (MRD) negativity rate of 77.5%
  • VEN plus azacitidine group had a CR rate of 52.9% and an MRD negativity rate of 51.6%
  • Significant improvement in CR and MRD negativity for DEC3-VEN compared to VEN plus azacitidine (P=0.034 and P=0.022 respectively)

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d38ehttps://doi.org/10.1182/blood-2025-3450
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial2025 · 1 citations
  2. 2Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS2025
  3. 3A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).2024 · 2 citations
  4. 4Short-term Group Venetoclax Combined with Azacitidine for Treating Newly Diagnosed Elderly Acute Myeloid Leukemia: A Retrospective Study2024
  5. 5Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia.2026